Acute Repetitive Seizures Market - Top Companies and Manufacturers

Companies Dominating the Acute Repetitive Seizures Landscape

Companies are developing novel antiepileptic drugs (AEDs) and innovative therapies specially targeting acute repetitive seizures. This includes creating medications with better efficacy, fewer side effects, and improved patient compliance. Moreover, significant investment in research and development helps in discovering new treatment options and understanding seizure mechanisms. Collaborations with other pharmaceutical companies and biotech firms help in co-developing new treatments and sharing technological expertise.

Some of the major key players in acute repetitive seizures market include:

UCB S.A., Belgium
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Neurelis, Inc.
Bausch Health Companies Inc.
Alexza Pharmaceuticals, Inc.
Veriton Pharma
Pfizer Inc.
Sanofi S.A.
Novartis Pharma AG
Neos Therapeutics, Inc.
Sage Therapeutics, Inc.

Browse Key Market Insights with Data Illustration:

Acute Repetitive Seizures Market Size & Share, Forecast Report 2037

In the News

In January 2020, Neurelis, Inc. announced that VALTOCO (diazepam nasal spray) has been approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of episodic, stereotypic episodes of frequent seizure activity (such as acute repetitive seizures, seizure clusters), in individuals with epilepsy aged 6 years and older, that differ from the patient's typical seizure pattern. Intravail is a component of VALTOCO's special formulation, which ensures dependable and constant absorption.
In May 2019, UCB S.A., Belgium announced today that the FDA has accepted a New Drug Application for NAYZILAM (midazolam) nasal spray CIV, the company's newest anti-epileptic drug (AED). This benzodiazepine is indicated for the acute treatment of episodic, stereotypic episodes of frequent seizure activity (i.e., acute repetitive seizures, seizure clusters), which are different from a patient's typical seizure pattern in patients with epilepsy 12 years of age and older. Patients and caregivers now have access to the first and only FDA-approved nasal treatment for seizure clusters with the advent of NAYZILAM.